HAYWARD, Calif., April 15, 2020 /PRNewswire/ -- Benitec Biopharma
Inc. (NASDAQ: BNTC) is pleased to announce that the previously
announced transaction to redomicile from Australia to the
United States has been fully implemented today. The
redomiciliation was approved by Benitec shareholders at a Scheme
Meeting held on March 26, 2020, and
confirmed by the Supreme Court of Queensland on March 30,
2020.
The shares of Benitec Biopharma, Inc. common stock issued today
in connection with the redomiciliation will trade on The Nasdaq
Capital Market LLC ("Nasdaq") under the symbol "BNTC", and Benitec
Biopharma Inc. will continue to be subject to the reporting
requirements of the U.S. Securities and Exchange Commission ("SEC")
and applicable corporate governance rules of Nasdaq. Further
details regarding the implementation of the redomiciliation can be
found in filings made today with the SEC.
About Benitec Biopharma, Inc.
Benitec Biopharma, Inc.
("Benitec" or the "Company") is a development-stage biotechnology
company focused on the advancement of novel genetic medicines, with
headquarters in Hayward,
California. The Company's proprietary "Silence and Replace"
approach combines DNA-directed RNA interference, or ddRNAi, with
gene therapy to create medicines that facilitate sustained
silencing of disease-causing genes following a single
administration. The Company is developing ddRNAi-based therapeutics
for chronic and life-threatening human conditions including
oculopharyngeal muscular dystrophy (OPMD), and chronic hepatitis B.
A comprehensive overview of the Company can be found on Benitec's
website at www.benitec.com.
Safe Harbor Statement:
This press release contains
"forward-looking statements" within the meaning of section 27A of
the US Securities Act of 1933 and section 21E of the US Securities
Exchange Act of 1934. Any forward-looking statements that may be in
this announcement are subject to risks and uncertainties relating
to the difficulties in Benitec's plans to develop and commercialize
its product candidates, the timing of the initiation and completion
of preclinical and clinical trials, the timing of patient enrolment
and dosing in clinical trials, the timing of expected regulatory
filings, the clinical utility and potential attributes and benefits
of ddRNAi and Benitec's product candidates, potential future
out-licenses and collaborations, the intellectual property position
and the ability to procure additional sources of financing.
Accordingly, you should not rely on those forward-looking
statements as a prediction of actual future results.
Investor Relations
M Group Strategic
Communications
Jay Morakis
Managing Director
Tel: +1 646 859 5951
Email: jmorakis@MGroupSC.com
View original
content:http://www.prnewswire.com/news-releases/benitec-biopharma-announces-the-completion-of-redomiciliation-to-the-united-states-301041000.html
SOURCE Benitec Biopharma Inc.